In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on MaxCyte (MXCT – Research Report), with a price target of ...

Meeting to be held in New York on March 25 hosted by BTIG.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven ...

MaxCyte stock opened at $3.29 on Wednesday. MaxCyte has a 52 week low of $2.76 and a 52 week high of $5.26. The firm’s 50-day simple moving average is $4.17 and its 200 day simple moving average ...

MaxCyte Inc (NASDAQ:MXCT) reported a strong year in 2024 with a return to core revenue growth and strategic improvements in operations. The acquisition of SecureDX is expected to enhance MaxCyte's ...

MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for MaxCyte in a report issued on Wednesday, March 12th.

(Alliance News) - MaxCyte Inc on Tuesday said its annual loss widened amid higher costs and falling revenue, but it remains optimistic about growth prospects for 2025. The Rockville, Maryland ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a company specializing in cell-engineering technologies for cell-based therapies, has filed its Form 10-K annual report for the fiscal year ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company focused on enabling technologies for cell therapeutics, has reported a mixed financial outcome for the fourth ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company focused on enabling technologies for cell therapeutics, has reported a mixed financial outcome for the fourth ...

MaxCyte is providing initial 2025 revenue guidance for core business revenue and SPL Program-related revenue: Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT) reported fourth quarter earnings that beat analyst expectations, but saw revenue plummet 45% YoY, sending shares down 10.4% in after-hours trading. The cell ...